Sheron Cogo

Sheron Cogo

Auto-generated profile, based on publicly available information

Sheron Cogo

LNC, INSERM, UMR1231, F-21079 Dijon, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Applied Surface Science
Verified
Journal Article
Closed access
LSLuciane Sopchenski Santos
Luciane Sopchenski Santos
SCS. Cogo
S. Cogo
MDM.F. Dias-Ntipanyj
M.F. Dias-Ntipanyj
SES. Elifio-Espósito
S. Elifio-Espósito
Ketul C PopatKetul C Popat
Ketul C Popat
PSPaulo Soares
Paulo Soares

1 June 2017 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
PPPraneetha Pulyala
Praneetha Pulyala
ASAkshay Singh
Akshay Singh
MDMarcela Ferreira Dias-Netipanyj
Marcela Ferreira Dias-Netipanyj
SCSheron Compos Cogo
Sheron Compos Cogo
LSLuciane Sopchenski Santos
Luciane Sopchenski Santos
Ketul C PopatKetul C Popat
Ketul C Popat

22 July 2020 in Cells
Verified
Journal Article
Open access
PDF file
EMElmallah Ismail Mohammed
Elmallah Ismail Mohammed
SCSheron Cogo
Sheron Cogo
ACAndrei A. Constantinescu
Andrei A. Constantinescu
ESElifio-Esposito Selene
Elifio-Esposito Selene
MAMohamed Abdelfattah
Mohamed Abdelfattah
OMOlivier Micheau
Olivier Micheau
Resistance of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis represents the major hurdle to the clinical use of TRAIL or its derivatives. The discovery and development of lead compounds able to sensitize tumor cells to TRAIL-induced cell death is thus likely to overcome this limitation. We recently reported that marine actinomycetes’ crude extracts could restore TRAIL sensitivity of the MDA-MB-231 resistant triple negative breast cancer cell line. We demonstrate in this study, that purified secondary metabolites originating from distinct marine actinomycetes (sharkquinone (1), resistomycin (2), undecylprodigiosin (3), butylcyclopentylprodigiosin (4), elloxizanone A (5) and B (6), carboxyexfoliazone (7), and exfoliazone (8)), alone, and in a concentration-dependent manner, induce killing in both MDA-MB-231 and HCT116 cell lines. Combined with TRAIL, these compounds displayed additive to synergistic apoptotic activity in the Jurkat, HCT116 and MDA-MB-231 cell lines. Mechanistically, these secondary metabolites induced and enhanced procaspase-10, -8, -9 and -3 activation leading to an increase in PARP and lamin A/C cleavage. Apoptosis induced by these compounds was blocked by the pan-caspase inhibitor QvD, but not by a deficiency in caspase-8, FADD or TRAIL agonist receptors. Activation of the intrinsic pathway, on the other hand, is likely to explain both their ability to trigger cell death and to restore sensitivity to TRAIL, as it was evidenced that these compounds could induce the downregulation of XIAP and survivin. Our data further highlight that compounds derived from marine sources may lead to novel anti-cancer drug discovery.